Inanovate, Inc

Inanovate is developing a low-cost blood test to monitor for breast cancer recurrence.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Sioux Falls, SD, US
  • Currency USD
  • Founded July 2010
  • Employees 5
  • Incorporation Type C-corp
  • Website inanovate.com

Company Summary

Inanovate has developed a patented blood analysis system (called the Bio-ID) that improves the cost, accessibility and accuracy of diagnostic tests. The first application of the Bio-ID is a new blood test to detect breast cancer recurrence when it can still be cured. Presently, over 40,000 women die every year from breast cancer in the US, the majority following a recurrence. That’s over 100 women dying each day. Studies have shown that early detection of recurrence can improve survival rates by up to 50%. We are addressing this need.
A 400 patient trial has already been completed with our clinical partners Sanford Health, and has shown our test can correctly identify over 8 in 10 cases of breast cancer, with only 3 in 10 false positives. We are now raising investment funds to help advance through clinical trials and commercial launch of our test.

Team

  • President & CEO

    Inanovate's Founder and co-inventor of the LAS technology. Mr Ure has over 8 yrs senior executive experience in the Life Science industry, with a further 7 yrs senior management and management consulting experience to start-up and high-growth companies. He holds a Bachelor of Science in Astrophysics, a Master of Science with Distinction in Radiation Physics from the University of Birmingham, UK, and an MBA Summa Cum Laude from Babson College, US.

  • Dr James Nelson
    CTO

    Inanovate’s CTO and co-inventor of the LAS technology. Dr. Nelson has over 16 yrs experience in developing and establishing advanced technologies for biomolecule screening, including 10 yrs as Manager of Technology Development at GlaxoSmithKline overseeing development and optimization of next generation multiplexing technologies. He holds a Bachelor of Science in Chemistry, and a PhD in Organic Chemistry.

  • Matthew Kostura
    CSO

    Dr. Kostura has over 25 years experience in developing advanced technologies for bio-molecule screening applications. Dr. Kostura has led the deployment and development of multiple immunoassay technologies in both GMP and GLP environments.  Dr. Kostura holds a PhD in Biology from University of Maryland.

  • Gregory Votaw
    Director of Engineering

    Mr. Votaw has over 16 years experience developing and implementing automation systems for the pharmaceutical industry and managing projects from concept through R&D and installation at research sites worldwide.  Mr Votaw holds an AE in Electronics Engineering.

  • Robert Nelson
    Director of Operations

    Mr. Nelson has over 20 years experience in development and manufacturing process control of micro-fluidic systems. Mr. Nelson holds a BS in Chemistry and an MS in Forensic Chemistry from Northeastern University.

  • Randall Marfin
    Director

    Mr. Marfin was a Founding team member and Vice President of Strategic Development at Luminex Corp. He helped oversee the growth of Luminex into a successful publicly traded company with a capitalization of $1 Billion.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free